Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Neurology

Volumn 73, Issue 20, 2009, Pages 1662-1669

  Christine, C W ^a   Starr, P A ^b   Larson, P S ^b   Eberling, J L ^c   Jagust, W J ^d   Hawkins, R A ^b   Vanbrocklin, H F ^b   Wright, J F ^e   Bankiewicz, K S ^a,b   Aminoff, M J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ENTACAPONE; FLUORO LEVO METHYL TYROSINE F 18; LEVODOPA; TRACER; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; LOW DRUG DOSE; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 73449128979     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c29356     Document Type: Article

References (20)

1. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 2007;113-120.
2. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006;14:564-570.
3. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinso-nian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
4. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70:1980-1983.
5. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 1975;12:189-198.
6. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
7. van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RA. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord 1994;9:84-88.
8. O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord 1998;13: 900-906.
9. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
10. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
11. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998;5:938-945.
12. Wright JF, Qu G, Tang C, Sommer JM. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel 2003;6:174-178.
13. Binder DK, Rau GM, Starr PA. Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery 2005;56:722-732.
14. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
15. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-2105.
16. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
17. Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol Ther 2006;14:571-577.
18. Bankiewicz KS, Plunkett RJ, Jacobowitz DM, Kopin IJ, Oldfield EH. Fetal nondopaminergic neural implants in parkinsonian primates: histochemical and behavioral studies. J Neurosurg 1991;74:97-104.
19. Sanftner LM, Sommer JM, Suzuki BM, et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 2005;194:476-483.
20. Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarbox-ylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 2001;4:324-330.